spacer
home > pmps > summer 2019 > planning your automation project
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Planning Your Automation Project

At the end of 2018, the Medicines and Healthcare products Regulatory Agency undertook a pharmacy-level recall of several batches of blood pressure and heart medication (valsartancontaining medicines) made by Mylan and Teva. This followed previous action across Europe recalling the same substance from Dexcel and Actavis. The precautionary measure was put in place to prevent any risk to patient safety after an impurity was identified as part of the manufacturing process.

When the stakes of manufacturing are so high, it is only natural to want to stick with tried and tested methods. Any issues that occur during the manufacturing process can have a significant impact on drug supply and patient care; for example, patients cannot just stop taking their blood pressure and heart medication.

However, incorporating automation equipment and software into the production line can lead to myriad benefits. A more robust, modern manufacturing approach can lead to fewer interruptions, fewer product failures, and greater confidence that drugs will meet clinical performance. While industries like automotive and aerospace have excelled in automation, many pharmaceutical companies are concerned that the technology is too complex a change.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Marketing Director by day, Jonathan Wilkins is also one of the most prolific Industry 4.0 writers in the industrial automation sector. A professional brand advocate and commercial marketing strategist, Jonathan has been part of the EU Automation team since its humble beginnings in 2009 and has over a decade of experience in marketing.
spacer
Jonathan Wilkins
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma enters into Development and Manufacturing Agreement with Synklino

Vilnius, Lithuania, and Copenhagen, Denmark – December 18th 2019 – Northway Biotechpharma, a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Synklino, a company active in developing a therapeutic protein based therapy as treatment for cytomegalovirus (CMV) infection, announced today that they entered into a Development and Manufacturing Agreement for the recombinant fusion protein SYNx, which Synklino aims to bring into clinical trials.
More info >>

White Papers

Exploring Protein Stability by nanoDSF

NanoTemper Technologies GmbH

nanoDSF determines thermal and chemical protein stability with ultra-high resolution and with unmatched reproducibility. The detection of the intrinsic tryptophan and tyrosin fluorescence enables measurements at close-to-native conditions in any buffer, even in the presence of detergents. nanoDSF is applied in antibody engineering, membrane protein research, formulation and quality control.
More info >>

 
Industry Events

INTERPHEX 2020

28-30 April 2020, Javits Center NYC


More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement